ClinicalTrials.gg
TerminatedNCT01741155Updated Oct 13, 2021

Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)

A Phase 2 interventional study of SPI-1620 and Docetaxel in Non Small Cell Lung Cancer (NSCLC), sponsored by Spectrum Pharmaceuticals, Inc. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-13.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study did not meet efficacy end point and did not enroll patients in the randomized phase.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
1,917th of 2,995
34 · median 56
Started
2013
with 100 others
Phase 2
1,078 of 3,368
119 open now
Registered
1,268th of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,917th largest by enrollment of the 2,995 interventional ones that give a count, is one of 101 that started in 2013, is one of 1,078 in phase 2, and was the 1,268th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to estimate and compare the objective response rate of SPI-1620 administered in combination with docetaxel in patients with NSCLC and to determine the safety of SPI-1620 when administered in combination with docetaxel.

Read the detailed description

This will be a two part study. In Single Arm Part, patients will receive 11 μg/m2 of SPI-1620 IV followed by docetaxel 75 mg/m2 IV. Cycles will continue every 3 weeks until progression or intolerable toxicity. Overall 27 patients will be enrolled in the Single Arm Part. If 6 or more responses (CR/PR) are observed in this group then the Randomized Part will be initiated.

In the Randomized Part approximately 200 patients (100 per arm) will be randomized to receive SPI-1620 plus docetaxel or docetaxel alone.

In the experimental arm, patients will receive 11 μg/m2 of SPI-1620 IV followed by docetaxel 75 mg/m2 IV administered in 3-week cycles until progression or intolerable toxicity. In the control arm, patients will receive 75 mg/m2 docetaxel in 3-week cycles until progression or intolerable toxicity.

03

Conditions studied

  • Non Small Cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed locally advanced or NSCLC that has failed one prior platinum-containing chemotherapy
  • as per v. 1.1
  • (ECOG) performance status of 0, 1 or 2
  • Adequate bone marrow, liver and renal function

Exclusion criteria

Exclusion Criteria:

  • More than one prior chemotherapy regimen for NSCLC
  • Known, uncontrolled central nervous system (CNS) metastases
  • Significant circulatory disorders in the past 6 mo.
  • Concomitant treatment with phosphodiesterase inhibitors
  • Uncontrolled orthostatic hypotension, asthma or (COPD)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Single Arm Part: SPI-1620 & Docetaxel

    Patients will receive 11 μg/m2 of SPI-1620 IV followed by docetaxel 75 mg/m2 IV. Cycles will continue every 3 weeks until progression or intolerable toxicity.

    Drug: SPI-1620 · Drug: Docetaxel

  • Experimental
    Randomized Part: SPI-1620 & Docetaxel

    Patients will receive 11 μg/m\^2 of SPI-1620 intravenous (IV) followed by docetaxel 75 mg/m\^2 IV administered in 3-week cycles until progression or intolerable toxicity.

    Drug: SPI-1620 · Drug: Docetaxel

  • Active comparator
    Randomized Part: Docetaxel

    Patients will receive 75 mg/m\^2 docetaxel in 3-week cycles until progression or intolerable toxicity.

    Drug: Docetaxel

Interventions

  • SPI-1620 11 μg/m2 administered intravenously over one minute.

  • Docetaxel: 75 mg/m2 administered as IV infusion.

    Also known as: Taxotere

06

What researchers measure

Primary outcomes

  1. Objective Response Rate(ORR) of SPI-1620

    To estimate and compare the objective response rate of SPI-1620 administered in combination with docetaxel in patients with NSCLC

    Time frame: Up to 2 years

Secondary outcomes

  1. Duration of Response (DoR)

    only in Randomized Part.

    Time frame: Up to 12 weeks

  2. Progression-free survival(PFS)

    only in Randomized Part

    Time frame: 2 years from the start of study treatment

  3. Overall survival (OS)

    Time frame: 2 years from the start of study treatment

  4. Safety of SPI-1620

    Periodic physical examinations with vital sign monitoring, safety laboratories and monitoring of adverse events will be performed.

    Time frame: Up to 2 years

07

Study locations

5 sites
  • Oncology Hematology Care Inc.
    Cincinnati, Ohio 45242, United States
  • Tennessee Oncology PLLC
    Chattanooga, Tennessee 37404, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23230, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2013 to primary completion in Jul 2015, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2012
First posted
Dec 4, 2012
StartActual
May 2013
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results delay requested
Sep 30, 2021
Last update
Oct 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01741155
Responsible party
Sponsor
First posted
Dec 4, 2012
Start date
May 2013
Primary completion
Jul 2015
Completion
Jul 2015
Last update
Oct 13, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sovateltide

Start the discussion